Portal de investigação
High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Alves, B
- Peixoto, J
- Macedo, S
- Pinheiro, J
- Carvalho, B
- Lima, J
- Lima, RT
Unidades de investigação
Abstract
Simple Summary Glioblastoma (GB) is a deadly tumor that demands for relevant biomarkers, particularly regarding patients' response to treatment. MMP-2, MMP-9, VEGFA, and YKL40 are important molecules, given their implication in the infiltrative and angiogenic phenotype of GBs. The purpose of this study was to assess the relationship between the expression of MMP-2, MMP-9, VEGFA, and YKL40 in GB tissues and the patients' response to temozolomide (first-line treatment) or bevacizumab (second-line treatment). Our results showed that increased VEGFA is significantly associated with an improved response to bevacizumab, while having no correlation with the response to temozolomide. Additionally, YKL40 expression may also be important regarding information about the extent of antiangiogenic treatment in GB patients. Glioblastoma (GB) is one of the deadliest human cancers. Many GB patients do not respond to treatment, and inevitably die within a median of 15-18 months post-diagnosis, highlighting the need for reliable biomarkers to aid clinical management and treatment evaluation. The GB microenvironment holds tremendous potential as a source of biomarkers; several proteins such as MMP-2, MMP-9, YKL40, and VEGFA have been identified as being differentially expressed in GB patient samples. Still to date, none of these proteins have been translated into relevant clinical biomarkers. This study evaluated the expression of MMP-2, MMP-9, YKL40, and VEGFA in a series of GBs and their impact on patient outcome. High levels of VEGFA expression were significantly associated with improved progression-free survival after bevacizumab treatment, thus having potential as a tissue biomarker for predicting patients' response to bevacizumab. Noteworthily, VEGFA expression was not associated with patient outcome after temozolomide treatment. To a lesser extent, YKL40 also provided significant information regarding the extent of bevacizumab treatment. This study highlights the importance of studying secretome-associated proteins as GB biomarkers and identifies VEGFA as a promising marker for predicting response to bevacizumab.
Dados da publicação
- ISSN/ISSNe:
- 2072-6694, 2072-6694
- Tipo:
- Article
- Páginas:
- 2196-
- Link para outro recurso:
- www.scopus.com
Cancers Multidisciplinary Digital Publishing Institute (MDPI)
Citações Recebidas na Web of Science: 1
Citações Recebidas na Scopus: 3
Documentos
- Não há documentos
Filiações
Keywords
- glioblastoma; secretome; biomarkers; immunohistochemistry; VEGFA; YKL40; MMP-2; MMP-9
Proyectos asociados
Selenium Clinical Supplementation In Autoimmune Thyroid Disease: A Portuguese Survey
Investigador Principal: Ana Paula Soares Dias Ferreira
Estudo Clínico Académico . 2022
Squamous cell carcinogenesis of the skin: Molecular characterization of prognostic therapeutic biomakers
Investigador Principal: Ana Paula Soares Dias Ferreira
Estudo Clínico Académico . 2022
Clinicopathological features and molecular biomarkers? role predicting papillary thyroid cancer patients? outcome: How to personalize and guide surgical treatment
Investigador Principal: Ana Paula Soares Dias Ferreira
Estudo Clínico Académico . 2022
Fatores do microambiente tumoral no cancro do ovário.
Investigador Principal: Ana Paula Soares Dias Ferreira
Estudo Clínico Académico . 2022
Citar a publicação
Alves B,Peixoto J,Macedo S,Pinheiro J,Carvalho B,Soares Dias Ferreira A,Lima J,Lima RT. High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma. Cancers. 2023. 15. (8):p. 2196-2196. IF:5,200. (2).
